Aclaris Therapeutics added to Russell 3000 and Russell 2000 Indexes, enhancing visibility for investors and market participation.
Quiver AI Summary
Aclaris Therapeutics, Inc. has announced its inclusion in the Russell 3000® and Russell 2000® Indexes following the annual reconstitution effective June 30, 2025. This reconstitution identifies the largest U.S. stocks based on market capitalization, and Aclaris's membership in the Russell 3000 ensures it is also part of the large-cap Russell 1000 or small-cap Russell 2000, as well as relevant growth and value indexes. Russell indexes, managed by FTSE Russell, are significant for investment managers due to their extensive use, overseeing approximately $10.6 trillion in assets. Aclaris, a clinical-stage biopharmaceutical firm, focuses on developing innovative treatments for immuno-inflammatory diseases. For more information, visit their website or follow them on social media.
Potential Positives
- Aclaris Therapeutics has been added to the Russell 3000® and Russell 2000® Indexes, enhancing its visibility among investors and highlighting its market standing.
- Membership in these indexes may attract new institutional investors who benchmark their portfolios against these widely recognized indices.
- Inclusion in the Russell indexes suggests strong market capitalization, which may enhance investor confidence and interest in the company's stock.
Potential Negatives
- Inclusion in the Russell 2000 Index may signal that the company's market capitalization is considered small by investor standards, which could impact perceptions of its growth potential.
FAQ
What is Aclaris Therapeutics' main focus?
Aclaris Therapeutics specializes in developing novel product candidates for immuno-inflammatory diseases.
When was Aclaris Therapeutics added to the Russell indexes?
Aclaris Therapeutics was added to the Russell 3000 and Russell 2000 Indexes on June 30, 2025.
What are the benefits of being included in the Russell 3000 Index?
Inclusion in the Russell 3000 Index provides automatic inclusion in the Russell 1000 or 2000 Indexes and enhances visibility among investors.
How does FTSE Russell determine index membership?
FTSE Russell determines index membership based on objective, market-capitalization rankings and style attributes of stocks.
Where can I find more information about Aclaris Therapeutics?
Additional information about Aclaris Therapeutics can be found at www.aclaristx.com and their social media accounts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACRS Hedge Fund Activity
We have seen 60 institutional investors add shares of $ACRS stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC removed 2,799,759 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,283,631
- SAMSARA BIOCAPITAL, LLC removed 2,385,060 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,649,141
- MILLENNIUM MANAGEMENT LLC added 2,175,101 shares (+111.0%) to their portfolio in Q1 2025, for an estimated $3,327,904
- TRIUM CAPITAL LLP removed 1,912,990 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,744,215
- DECHENG CAPITAL LLC added 1,775,069 shares (+78.3%) to their portfolio in Q1 2025, for an estimated $2,715,855
- MORGAN STANLEY added 1,343,800 shares (+125.4%) to their portfolio in Q1 2025, for an estimated $2,056,014
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,302,694 shares (+1648.0%) to their portfolio in Q1 2025, for an estimated $1,993,121
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACRS Analyst Ratings
Wall Street analysts have issued reports on $ACRS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 05/28/2025
- H.C. Wainwright issued a "Buy" rating on 05/14/2025
- Scotiabank issued a "Outperform" rating on 03/07/2025
To track analyst ratings and price targets for $ACRS, check out Quiver Quantitative's $ACRS forecast page.
Full Release
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000 ® and small-cap Russell 2000 ® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025.
The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.
For more information on the Russell 3000 ® Index, the Russell 2000 ® index, and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website .
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]
